Global decentralized studies will become a standard clinical trial design approach
The Pharma Data
MARCH 20, 2021
Sponsors and CROs will continue to be eager to bounce back and accelerate the drug development process after significant delays caused by the pandemic,β Reites said. . These focus areas will materialize in study designs as hybrid decentralized approaches that support global programs,β Reites said. βIn Source link: [link].
Let's personalize your content